CDC issues new guidelines for RSV vaccines, citing side-effect concerns

[Bayard]

The CDC has clarified and narrowed its recommendations for which older adults should get an RSV vaccine.

The Centers for Disease Control and Prevention (CDC) has narrowed its recommendations for which older adults should get a vaccine against respiratory syncytial virus (RSV). It now states that only adults 75 and older, or those ages 60 to 74 who are at high risk, should get the shot. That's partly because the vaccine may slightly increase the risk of a rare side effect that can sometimes lead to paralysis or death.

RSV circulates seasonally and hospitalizes 60,000 to 160,000 older adults in the U.S. each year. An estimated 6,000 to 10,000 people in this age group die due to RSV infection annually. The first-ever RSV vaccine was approved last year, and a total of three have now been approved for use in people ages 60 and up: GSK's Arexvy, Pfizer's Abrysvo and, most recently, Moderna's mResvia. Initially, the CDC said all adults ages 60 and older could get one dose of one of these RSV vaccines after discussing it with their doctor.

Now, "based on currently available evidence," the CDC's Advisory Committee on Immunization Practices has concluded that the benefits of RSV vaccination do not clearly outweigh the potential harms in adults ages 60 to 74 who don't have risk factors for severe RSV. However, people in this age range who do have risk factors could still benefit. With that in mind, "providers should continue to have flexibility in offering RSV vaccine to patients they assess to be at increased risk for severe disease even if they do not fall into an explicitly named risk category," the CDC noted in a Morbidity and Mortality Weekly Report published Tuesday (Aug. 6).

Thus, people ages 60 to 74 can still consider the shot if they are at high risk of severe RSV infections. That would apply to people with chronic heart disease or a weakened immune system, as well as those who live in long-term care facilities such as nursing homes. Adults who have already received an RSV vaccine "should not receive another dose," the report notes. The updated recommendations were issued because of higher-than-expected rates of Guillain-Barré syndrome (GBS) tied to the vaccines. GBS can cause tingling, numbness and muscle weakness and sometimes progress to paralysis. In severe cases, the condition can affect muscles that support breathing and thus be life-threatening.


https://www.livescience.com/health/medicine-drugs/cdc-issues-new-guidelines-for-rsv-vaccines-citing-side-effect-concerns

[Celerity]

1. ....